RCR: Scotland’s 28% radiologist gap warns UAE cancer operators on staffing

Royal College of Radiologists (RCR) data published on 18 June 2026 shows NHS Scotland is 28% short of radiologists and 18% short of clinical oncologists.

For UAE cancer operators, the so-what is immediate: oncology growth depends on enough imaging, reporting, treatment planning and infusion capacity to move patients through one pathway.

The most exposed readers are HR directors, COOs, medical directors and CFOs reviewing oncology plans in 2026. Dubai providers answer to the Dubai Health Authority (DHA), Abu Dhabi and Al Ain providers answer to the Department of Health Abu Dhabi (DOH), and Northern Emirates providers answer to the Ministry of Health and Prevention (MOHAP).

What the RCR data says

The RCR report, covered by STV News after the Glasgow Times news item, was based on responses from 100% of cancer centre and radiology department leaders in Scotland and across the UK. In Scotland, every cancer centre reported treatment delays linked to staff shortages.

• Six in 10 radiology and cancer leaders said shortages were causing patients’ conditions to worsen.
• 100,000 people in Scotland waited more than six weeks for a scan or diagnostic test in 2025.
• 71% of patients started cancer treatment within 62 days of referral in 2025, against a 95% target.
• By 2030, the RCR projects Scotland could be 37% short of radiologists and 58% short of clinical oncologists.

“For the first time, our census shows that patients’ conditions are deteriorating because of workforce shortages.”
Dr Stephen Harden, president, Royal College of Radiologists

Why UAE operators should care

GLOBOCAN 2022 estimated 5,526 new cancer cases in the UAE, led by 1,142 breast cancer cases, 550 colorectal cancer cases and 444 thyroid cancer cases. Those cases create demand for radiology, pathology, medical oncology, surgery, radiotherapy and survivorship clinics.

For UAE COOs, the Scotland data is a capacity-planning case study. A cancer programme can sell same-week consultations, but the clinical clock is set by scan slots, report turnaround, tumour board scheduling and drug chair capacity.

DHA, DOH and MOHAP inspections add documentation work around licensing, privileging, consent, medication safety and radiation governance. A thin staffing model leaves little room for annual leave, visa delays or credentialing gaps.

For CFOs, the P&L risk shows up in two places. Late reporting can push patients to competitors with faster imaging or international second opinions, while temporary staffing, external reporting and overseas referrals can turn an oncology line into a margin problem.

What to check before expansion

UAE boards reviewing oncology growth in 2026 should ask for a staffing dashboard before approving new equipment or marketing spend. The dashboard should separate full-time, visiting and outsourced capacity for radiologists, radiation oncologists, medical oncologists, oncology nurses, physicists, dosimetrists and tumour board coordinators.

HR teams should map licence timelines by regulator. A DHA-licensed oncologist cannot simply cover a DOH facility without the correct approval, and MOHAP facilities have their own credentialing route.

The number to remember is 28%: that is the current radiologist gap reported for NHS Scotland. If a UAE provider is adding oncology demand in 2026, the board should test whether reporting cover, tumour board cover and treatment sign-off capacity can absorb resignations, leave and licensing delays.